This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Medical Instruments Stock Outlook: Long-Term Prospects Bright
by Zacks Equity Research
Research and development in the medical instruments industry is on the rise. FDA's approval of gene therapy for inherited renal disease and Big Data for healthcare set to revolutionize the field.
Looking for a Top Momentum Pick? Why CryoLife (CRY) is a Great Choice
by Zacks Equity Research
Does CryoLife (CRY) have what it takes to be a top stock pick for momentum investors? Let's find out.
CryoLife (CRY) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
CryoLife (CRY) delivered earnings and revenue surprises of 42.86% and 9.07%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Momentum Trading Strategy, Trump Cancels Kim Meeting | Free Lunch
by Ryan McQueeney
Ryan McQueeney discusses how stocks are moving in the wake of news that President Trump has cancelled his meeting with North Korean leader Kim Jung Un and later recaps the latest macroeconomic data. On the second half of the show, Ryan is joined by Zacks momentum guru Dave Bartosiak to talk trading strategies in today's market.
CryoLife (CRY) Stock Gains 9.5% on Impressive Q1 Earnings
by Zacks Equity Research
CryoLife's (CRY) shares gain on growth in all product lines along with strong performance in all geographies in Q1.
Zacks.com featured highlights include: Mattel, Clean Harbors, Live Nation, CryoLife and Archrock
by Zacks Equity Research
Zacks.com featured highlights include: Mattel, Clean Harbors, Live Nation, CryoLife and Archrock
Discard These 5 Toxic Stocks or Sell Short for Profits
by Zacks Equity Research
Overpriced toxic stocks are generally susceptible to external shocks and loaded with a high level of debt.
CryoLife to Buy JOTEC, Preliminary Revenue Result Out for Q3
by Zacks Equity Research
CryoLife (CRY) gained access to the $2-billion global market for stent grafts through JOTEC deal.
DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay
by Zacks Equity Research
On Jul 12, we issued an updated research report on NY-based DENTSPLY SIRONA Inc. (XRAY) -- a global leader in the design, development, manufacture and marketing of dental consumables and dental laboratory products.
C.R. Bard (BCR) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
C.R. Bard's (BCR) solid performance in the Vascular, Urology and Surgical Specialties were the key highlights of the second quarter.